ProfPaul McNally

Current Research
One of Paul’s main areas of research interest is in early lung disease in children with Cystic Fibrosis (CF). He established, with colleagues in Ireland, a longitudinal multi-centre study in this area (SHIELD-CF) resulting in several important collaborations and outputs over a ten-year period. Paul has been a local and national lead on more than 20 interventional clinical trials in children with CF. Paul led the design of a longitudinal real-world phase 4 study examining the impact of a new CFTR modulator therapy to children aged 6-11 with CF in Ireland (CFORMS) and is currently leading a multi-centre real-world phase 4 study of triple combination CFTR modulator compounds in 8 centres in the UK and Ireland (RECOVER: NCT04602468). Paul and his team have received funding for a further longitudinal natural history study in children with CF in 13 sites in the UK and Ireland (ENHANCE: NCT05986045) that will run from 2024 to 2029.